Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Deacon

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Cancer Research|November 21, 1998
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 geneK T Hogan, D P Eisinger, S B Cupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesC L Slingluff, G Yamshchikov, P Neese, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Cancer Research|November 21, 1998
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 geneK T Hogan, D P Eisinger, S B Cupp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesC L Slingluff, G Yamshchikov, P Neese, et al.
Pageof 4